

Cleansing Notice under Section 708A(5)(e)

MINNEAPOLIS, United States and BRISBANE, Australia 30 October 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces that on 28 October 2025 (AEDT) / 27 October 2025 (United States Eastern Time), the Company issued 2,346,936 shares of Common Stock (**Shares**) to investors pursuant to the Company's capital raising announced by the Company on 28 October 2025 (AEDT).

The Company is also intending to issue 2,788,064 new CHESS Depositary Interests in the Company (**CDIs**) pursuant to the capital raising, which is now expected to settle on 3 November 2025 (Australia time).

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the **Corporations Act**)¹, that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;²
2. as at the date of this Notice, the Company has complied with:
 - (a) section 601CK of the Corporations Act; and
 - (b) sections 674 and 674A of the Corporations Act; and
3. as at the date of this Notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

¹ As modified by ASIC Corporations (Offers of CHESS Depositary Interests) Instrument 2025/180 and ASIC Instrument 24-0923.

² The reference to disclosure is a reference to a disclosure document issued under the Corporations Act (such as a prospectus).



About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR[®] Transcatheter Heart Valve (**THV**), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[®] THV is made using a single piece of molded ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information:

Investor Relations

investors@anteristech.com

Debbie Ormsby

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com

Malini Chatterjee, Ph.D.

Blueprint Life Science Group

+1 917 330 4269

Website www.anteristech.com

X [@AnterisTech](https://twitter.com/AnterisTech)

LinkedIn <https://www.linkedin.com/company/anteristech>

